Our results describe a new mechanism by which bort suppresses self‐renewal of LSC by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐arranged leukaemia, indicating that bort might be a potential drug for AML patients with MLL rearrangements. This evidence concerns the gene KMT2A and acute myeloid leukemia.